NO975678L - Stabile reagenser for fremstilling av radiofarmasöytika - Google Patents

Stabile reagenser for fremstilling av radiofarmasöytika

Info

Publication number
NO975678L
NO975678L NO975678A NO975678A NO975678L NO 975678 L NO975678 L NO 975678L NO 975678 A NO975678 A NO 975678A NO 975678 A NO975678 A NO 975678A NO 975678 L NO975678 L NO 975678L
Authority
NO
Norway
Prior art keywords
radiopharmaceuticals
preparation
stable reagents
reagents
stable
Prior art date
Application number
NO975678A
Other languages
English (en)
Norwegian (no)
Other versions
NO975678D0 (no
Inventor
Michael Sworin
Milind Rajopadhye
Thomas David Harris
David Scott Edwards
Edward Hollister Cheesman
Shuang Liu
Original Assignee
Du Pont Merck Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma
Publication of NO975678D0 publication Critical patent/NO975678D0/no
Publication of NO975678L publication Critical patent/NO975678L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/008—Peptides; Proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO975678A 1995-06-07 1997-12-05 Stabile reagenser for fremstilling av radiofarmasöytika NO975678L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/476,296 US5750088A (en) 1993-03-30 1995-06-07 Stable hydrazones linked to a peptide moiety as reagents for the preparation of radiopharmaceuticals
PCT/US1996/009766 WO1996040637A1 (en) 1995-06-07 1996-06-07 Stable reagents for the preparation of radiopharmaceuticals

Publications (2)

Publication Number Publication Date
NO975678D0 NO975678D0 (no) 1997-12-05
NO975678L true NO975678L (no) 1998-02-06

Family

ID=23891282

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975678A NO975678L (no) 1995-06-07 1997-12-05 Stabile reagenser for fremstilling av radiofarmasöytika

Country Status (29)

Country Link
US (2) US5750088A (enExample)
EP (1) EP0832068B1 (enExample)
JP (1) JPH11507364A (enExample)
KR (1) KR19990022573A (enExample)
CN (1) CN1192733A (enExample)
AR (1) AR003959A1 (enExample)
AT (1) ATE233241T1 (enExample)
AU (1) AU718683B2 (enExample)
BR (1) BR9609003A (enExample)
CA (1) CA2222183A1 (enExample)
CZ (1) CZ380197A3 (enExample)
DE (1) DE69626392T2 (enExample)
EA (1) EA000742B1 (enExample)
EE (1) EE9700313A (enExample)
ES (1) ES2193245T3 (enExample)
HR (1) HRP960250A2 (enExample)
HU (1) HUP9901469A3 (enExample)
IL (1) IL118468A0 (enExample)
LT (1) LT4380B (enExample)
LV (1) LV12044B (enExample)
MX (1) MX9709126A (enExample)
MY (1) MY133974A (enExample)
NO (1) NO975678L (enExample)
NZ (1) NZ310799A (enExample)
PL (1) PL323995A1 (enExample)
SI (1) SI9620076B (enExample)
SK (1) SK163497A3 (enExample)
WO (1) WO1996040637A1 (enExample)
ZA (1) ZA964854B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2249025A1 (en) * 1996-03-13 1997-09-18 Du Pont Pharmaceuticals Company New ternary radiopharmaceutical complexes
ATE240123T1 (de) * 1996-10-07 2003-05-15 Bristol Myers Squibb Pharma Co Radiopharmazeutische mittel zur bildgebung von infektionen und entzündungen
US6416733B1 (en) 1996-10-07 2002-07-09 Bristol-Myers Squibb Pharma Company Radiopharmaceuticals for imaging infection and inflammation
US20030124053A1 (en) * 1996-10-07 2003-07-03 Barrett John Andrew Radiopharmaceuticals for imaging infection and inflammation
US6403054B1 (en) 1997-05-28 2002-06-11 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6537520B1 (en) * 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
WO1999051628A1 (en) * 1998-04-03 1999-10-14 Du Pont Pharmaceuticals Company Radiopharmaceuticals for imaging infection and inflammation and for imaging and treatment of cancer
HRP990317A2 (en) * 1998-10-13 2000-06-30 Du Pont Pharm Co A process for the preparation of a thrombus imaging agent
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) * 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
CA2727746A1 (en) 1998-12-18 2000-06-22 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
BR0010517A (pt) * 1999-03-26 2002-01-08 Du Pont Pharm Co Métodos de formação de imagem de um trombo, de um êmbolo pulmonar, de um trombo arterial e de um trombo coronariano
US6808698B1 (en) 1999-03-26 2004-10-26 Bristol-Myers Squibb Pharma Company Method for localization of blood clots
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US20030220646A1 (en) * 2002-05-23 2003-11-27 Thelen Sarah L. Method and apparatus for reducing femoral fractures
US6534038B2 (en) 2000-04-07 2003-03-18 Bristol-Myers Squibb Pharma Company Ternary ligand complexes useful as radiopharmaceuticals
JP2004512382A (ja) 2000-11-03 2004-04-22 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 心臓灌流および心臓炎症の２核種同時イメージング
GB0031592D0 (en) * 2000-12-28 2001-02-07 Nycomed Amersham Plc Stabilised radiopharmaceutical compositions
HUP0401904A3 (en) * 2001-08-08 2009-01-28 Bristol Myers Squibb Pharma Co Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US6838074B2 (en) 2001-08-08 2005-01-04 Bristol-Myers Squibb Company Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
US7317104B2 (en) 2003-06-13 2008-01-08 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
US7319149B2 (en) * 2003-06-13 2008-01-15 Bristol-Myers Squibb Pharma Company Chelants and macrocyclic metal complex radiopharmaceuticals thereof
BRPI0412824A (pt) * 2003-07-24 2006-09-26 Bracco Imaging Spa composições radiofarmacêuticas estáveis e métodos para suas preparações
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
EP1896086A1 (en) * 2005-06-30 2008-03-12 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
EP1950205A4 (en) * 2005-10-19 2010-07-07 Dainippon Sumitomo Pharma Co METHOD FOR STABILIZING AN ISOXAZOLE COMPOUND
US7465795B2 (en) * 2005-12-20 2008-12-16 Astrazeneca Ab Compounds and uses thereof
RU2008122405A (ru) * 2005-12-20 2010-01-27 Астразенека Аб (Se) Замещенные производные циннолина в качестве модуляторов гамма-рецепторов и способ их синтеза
US8034815B2 (en) 2007-01-11 2011-10-11 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
TW200911760A (en) * 2007-06-19 2009-03-16 Astrazeneca Ab Compounds and uses thereof
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
ES2481042T3 (es) 2008-12-29 2014-07-29 Sanofi Derivados de 2-piridin-2-il-pirazol-3(2H)-ona, su preparación y uso terapéutico como activadores de HIF
FR2949468B1 (fr) * 2009-08-28 2011-09-30 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
AU2009334570B2 (en) * 2008-12-29 2016-06-09 Sanofi Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
FR2967671A1 (fr) * 2010-11-24 2012-05-25 Pf Medicament Complexe de technetium 99m en tant qu'outil de diagnostic in vivo des tumeurs cancereuses
CN110818624B (zh) * 2019-11-22 2022-11-22 华东理工大学 吡啶季铵盐腙类化合物及制备方法与在抗菌或香料缓释中的应用
CN112999369B (zh) * 2021-03-03 2022-02-25 江苏元本生物科技有限公司 一种her2亲合体放射性核素标记物组合物及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4427646A (en) 1981-04-02 1984-01-24 Research Corporation Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
CA1300608C (en) * 1985-05-10 1992-05-12 Edward A. Deutsch 99 mtc (iii) myocardial imaging agents which are non-reducable in vivo
GB8624272D0 (en) * 1986-10-09 1986-11-12 Amersham Int Plc Cationic complexes of tc-99m
US5217705A (en) 1987-09-25 1993-06-08 Neorx Corporation Method of diagnosing blood clots using fibrin-binding proteins
WO1989005150A1 (en) 1987-12-10 1989-06-15 La Jolla Cancer Research Foundation Conformationally stabilized cell adhesion peptides
US5300278A (en) * 1988-03-09 1994-04-05 Cis Bio International Process for the preparation of 99m Tc, 186 Re or 188 Re nitride complexes usable as radiopharmaceutical products
GB8808414D0 (en) * 1988-04-11 1988-05-11 Amersham Int Plc Ligands & cationic complexes thereof with technetium-99m
EP0412115A4 (en) 1988-04-29 1991-11-13 New England Deaconess Hospital Corporation Hybrid peptides and methods of their use
US5002754A (en) * 1988-06-15 1991-03-26 University Of Cincinnati Technetium (III/II) imaging agents
HUT55799A (en) 1988-09-29 1991-06-28 Biogen Inc Process for producing hirudine-like peptides
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
US5270030A (en) 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
GB8902362D0 (en) * 1989-02-03 1989-03-22 Amersham Int Plc Cationic complexes of technetium-99m
US5206370A (en) * 1989-02-24 1993-04-27 Johnson Matthey, Inc. Certain pyridyl hydrazines and hydrazides useful for protein labeling
IL93432A (en) * 1989-02-24 1994-02-27 Johnson Mathey Inc Hydrazines and hydrazides, their conjugates with macromolecules, and such conjugates labeled with metallic ions
US4957728A (en) * 1989-05-19 1990-09-18 University Of Cincinnati Kit for preparing Tc (III)-99m myocardial imaging agents that are effective in humans
US4917879A (en) * 1989-05-19 1990-04-17 University Of Cincinnati 99MTC(III) myocardial imaging agents that are effective in humans
GB8914020D0 (en) 1989-06-19 1989-08-09 Antisoma Ltd Synthetic peptides for use in thrombus detection
EP0410537A1 (en) 1989-07-28 1991-01-30 Merck & Co. Inc. Fibrinogen receptor antagonists
GB8919488D0 (en) * 1989-08-29 1989-10-11 Amersham Int Plc New cores for technetium radiopharmaceuticals
ZA907743B (en) 1989-10-03 1991-07-31 Merrell Dow Pharma Radiolabeled anticoagulant peptides
US5086069A (en) 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
FR2664166A1 (fr) * 1990-07-04 1992-01-10 Cis Bio Int Procede de preparation de complexes nitruro de metaux de transition utilisables comme produits radiopharmaceutiques ou pour la synthese de nouveaux produits radiopharmaceutiques.
IL99537A (en) 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
AU8730691A (en) * 1990-09-28 1992-04-28 Neorx Corporation Polymeric carriers for release of covalently linked agents
US5112594A (en) * 1991-04-04 1992-05-12 Mallinckrodt Medical, Inc. Kit for preparing a technetium-99m myocardial imaging agent
US5925331A (en) 1992-05-21 1999-07-20 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
CA2101942C (en) 1991-02-08 2001-01-30 Richard T. Dean Technetium-99m labeled polypeptides for imaging
FR2679452B1 (fr) * 1991-07-22 1993-11-12 Cis Bio International Produit radiopharmaceutique ayant notamment un tropisme cerebral, comportant un complexe nitruro d'un metal de transition, et son procede de preparation.
US5362852A (en) * 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
GB2268494B (en) 1992-07-08 1996-08-21 Kenneth Francis Prendergast Imaging compositions
FR2698272B1 (fr) * 1992-11-20 1994-12-30 Cis Bio Int Procédé de marquage cellulaire au moyen de complexes nitruro-bis (dithiocarbamato)Tc-99m et trousse pour la mise en Óoeuvre de ce procédé.
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders

Also Published As

Publication number Publication date
EA199800025A1 (ru) 1998-06-25
LV12044A (lv) 1998-05-20
DE69626392D1 (de) 2003-04-03
LV12044B (en) 1998-09-20
EE9700313A (et) 1998-06-15
NO975678D0 (no) 1997-12-05
NZ310799A (en) 2000-01-28
PL323995A1 (en) 1998-04-27
AU718683B2 (en) 2000-04-20
LT4380B (lt) 1998-09-25
AR003959A1 (es) 1998-09-30
AU6166196A (en) 1996-12-30
IL118468A0 (en) 1996-09-12
ES2193245T3 (es) 2003-11-01
EP0832068B1 (en) 2003-02-26
MY133974A (en) 2007-11-30
HRP960250A2 (en) 1997-12-31
WO1996040637A1 (en) 1996-12-19
HUP9901469A3 (en) 2000-02-28
DE69626392T2 (de) 2004-04-22
US5750088A (en) 1998-05-12
EP0832068A1 (en) 1998-04-01
EA000742B1 (ru) 2000-02-28
MX9709126A (es) 1998-03-31
SI9620076B (sl) 2000-02-29
CA2222183A1 (en) 1996-12-19
LT97191A (en) 1998-04-27
US6015904A (en) 2000-01-18
SK163497A3 (en) 1998-10-07
CZ380197A3 (cs) 1998-07-15
CN1192733A (zh) 1998-09-09
ATE233241T1 (de) 2003-03-15
ZA964854B (en) 1997-12-08
KR19990022573A (ko) 1999-03-25
BR9609003A (pt) 1999-12-14
HUP9901469A2 (hu) 1999-08-30
SI9620076A (sl) 1998-08-31
JPH11507364A (ja) 1999-06-29

Similar Documents

Publication Publication Date Title
NO975678D0 (no) Stabile reagenser for fremstilling av radiofarmasöytika
DK0770615T3 (da) Fremgangsmåde til fremstilling af dihalogenazolopyrimidiner
DK0747116T3 (da) Fremgangsmåde til fremstilling af mikrokapselsammensætninger
FI973281L (fi) Menetelmä tiettyjen atsasykloheksapeptidien valmistamiseksi
DE69522165D1 (de) Mikrokreisel
DK0768310T3 (da) Fremgangsmåde til fremstilling af imidazo-benzodiazepin-derivater
DK0877738T3 (da) Fremgangsmåde til fremstilling af phenylimidazolidinderivater
NO20000189L (no) Fremgangsmõte for fremstilling av heparin
FI955177L (fi) Paakkuuntumisen estoaine
DE69625681D1 (de) Kinderwagen
DE69624334D1 (de) Fixiervorrichtung
NO950902L (no) Fremgangsmåte for fremstilling av metylklorsilaner
NO996432L (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
DK1012152T3 (da) Fremgangsmåde til fremstilling af oxazaphosphorin-2-aminer
DK0721929T3 (da) Fremgangsmåde til fremstilling af hydroxyalkoxybenzophenoner
DK0863874T3 (da) Fremgangsmåde til fremstilling af dioxoazabicyclohexaner
DK0729971T3 (da) Fremgangsmåde til fremstilling af ivermectin
NO984286L (no) FremgangsmÕte for fremstilling av H2S for en isotopanalyse
NO20003077L (no) FremgangsmÕte for fremstilling av klorbenzooksazolen
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner
DK0921111T3 (da) Fremgangsmåde til fremstilling af substituerede anthraquinoner
NO20002476D0 (no) FremgangsmÕte for fremstilling av formylimidazoler
PT761766E (pt) Compostos assimetricos de trifenilenodioxazina
FI932887A0 (fi) Foerbaettrat foerfarande foer framstaellning av 4-nitro-3-trifluorometylanilin
FI1463U1 (fi) Sjaelvbevattning utnyttjande kruksystem

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application